FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma
The U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel) as the first CAR T-cell therapy for marginal zone lymphoma in the United States. The approval marks a significant advancement in treatment options for patients with this rare form of blood cancer.